Sea Buckthorn for Vaginal Dryness: The Trial in Full

The trial, in full

Published in Maturitas in 2014, the study enrolled 116 postmenopausal women with vaginal atrophy symptoms and randomized them to 3 grams of sea buckthorn oil or placebo daily for three months. The headline result: the odds of improved vaginal epithelial integrity were about three times higher on oil than on placebo (odds ratio 3.1, 95% CI 1.11 to 8.95).

One caveat belongs right beside that number, and almost nobody prints it. When the researchers re-ran the analysis on only the women who took their capsules as directed, the effect stopped being significant (odds ratio 2.9, 95% CI 0.99 to 8.35). That interval crosses 1, so the stricter analysis cannot rule out no effect at all. The headline figure is the one everyone quotes. Both belong on this page.

Two secondary results matter as much as the headline. Vaginal pH did not change, and the maturation index did not change. In plain terms, the vaginal tissue did not respond the way it responds to estrogen. The oil was helping by some other route. It is the best-evidenced entry on the women’s hub.

Why the non-hormonal part is the story

Topical estrogen is the standard, most effective treatment for vaginal dryness after menopause, and many women cannot or do not want to use it: some after estrogen-sensitive cancers, some by choice. An option that helps without touching estrogen pathways fills a real gap for exactly those women. The honest limit: the trial’s effect was modest compared with what topical estrogen delivers, so read it as support for women seeking a non-hormonal route, not as a rival to the standard care.

A bigger trial, but a different product

In 2025 a much larger study landed, and it is the one to watch. It also carries a caveat that changes everything about how you read it. Researchers at a Shanghai hospital randomized 377 postmenopausal women heading into a colposcopy, the close look at the cervix that atrophied tissue makes hard to read, and 368 of them finished. One group got no pretreatment, one got a compound sea buckthorn oil suppository placed in the vagina, and one got an estrogen ointment, each for two weeks. Both active groups restored the vaginal lining enough to make the exam readable, well ahead of the untreated group at P below 0.001, and the two active groups did not differ significantly from each other. The authors’ own conclusion calls the suppository not inferior to estrogen. We print it more plainly than that. The trial set no non-inferiority margin in advance and was never designed to prove equivalence, so what it shows is no difference detected in one study, and that is not the same claim.

The side effect split is the cleanest part of the result, and it needs both halves. Whole-body complaints landed on the estrogen side, breast discomfort in 5.6% and dizziness or headache in 4%, against nobody in the suppository arm, a gap the study called statistically significant. Local complaints ran the other way. Ten women in the suppository arm reported vaginal discomfort against five in the estrogen arm, a difference too small for the study to call real either way. So the honest line is fewer whole-body side effects, not fewer side effects overall.

Here is the caveat, and it is the whole point. That product goes into the vagina. It is not a capsule you swallow. The Larmo 2014 trial this page is built on tested oral oil taken by mouth. So the 2025 result does not say an oral supplement matches estrogen. It says a local sea buckthorn suppository, applied right where the problem is, could not be told apart from a local estrogen ointment over two weeks on the exam-readiness measures. Two different routes, two different products, and only the topical one has ever been measured head to head with estrogen.

A few more things keep it honest. The suppository was a compound formula, so sea buckthorn was one ingredient among others, not a pure sea buckthorn arm, and it was a licensed pharmacy product rather than anything sold on a supplement shelf. The trial was open-label, because the two treatments leave different traces and could not be disguised, so everyone knew what they were getting. The women in it were not there for dryness. They were there because a smear or an HPV test came back abnormal, and 94% carried a high-risk HPV infection. Nobody measured a dryness symptom. The yardstick was whether a cervical exam became readable, a clinical stand-in for atrophy rather than a diary of how anyone felt. It is a real, sizeable, encouraging result for the topical route, and it is still one trial. If you want a sea buckthorn option that has gone toe to toe with estrogen, the honest version is a prescribed vaginal product, not the capsules the rest of this page describes, and never a capsule meant for swallowing used somewhere it was not made for.

Why it plausibly works

The oil concentrates palmitoleic acid and other fatty acids, and the vaginal lining is a mucous membrane, the same tissue family as the tear film (where a separate 100-person trial found benefit at 2 grams daily) and skin (where two trials found hydration gains). Three mucosal surfaces, three positive human trials at gram doses. The pattern is genuinely interesting. It is still one trial per surface, and replication is the step that turns interesting into established. The dry-eye study ran through a Finnish winter at 2 grams daily, covered on the dry eyes page. The skin trials used 1 to 2 grams daily for about three months, graded on the dry skin page. Same plant, same dose range, same tissue family, three times. No other sea buckthorn claim has that pattern behind it.

The pharmacy lane

Before any capsule, the pharmacy shelf offers two workhorses with real data behind them. Vaginal moisturizers are used on a schedule, several times a week, and they rehydrate tissue over time. Lubricants are event-level, used when needed, and they reduce friction rather than change tissue. Both are cheap, hormone-free, and fast. The studied sea buckthorn route is none of those things: it is systemic, slow, and measured in months. The honest stack for most women is moisturizer first, oil as an adjunct if the problem persists, and a doctor if both fail. That sequence respects both the evidence and your patience.

When dryness is not menopause

This trial enrolled postmenopausal women, but dryness has other causes, and the cause decides the treatment. Breastfeeding suppresses estrogen and commonly causes dryness, which is why the breastfeeding page exists: that version is temporary, and the supplement rules there are stricter. Medications do it too, including antihistamines, some antidepressants, isotretinoin, and some hormonal contraceptives. Cancer treatment can cause severe dryness that needs specialist care. And pain, bleeding, or discharge alongside dryness is not a supplement question at all. Same symptom, different problems, different answers.

Reading the product pages

Products citing this trial tend to upgrade its language. “Clinically proven for feminine health” inflates one modest finding in one group of postmenopausal women into a blanket promise. Check the dose math too: the trial used 3 grams daily, which is six standard 500 mg softgels, and a label suggesting one capsule a day is not selling the studied regimen. A “proprietary feminine blend” is worse, because then even the ingredient amount is hidden. Our roundup of the best sea buckthorn capsules scores the labels that do print the oil split and lists what each bottle costs per day, so you can multiply up to six softgels before you commit to three months. The trial used one oil, at one dose, for three months. Anything else is a different, untested product wearing the trial’s clothes.

What the trial could not answer

One trial is one trial. Nobody has replicated it, tested other doses, or followed women past three months, so nothing is known about whether the benefit holds, grows, or fades at six months. The 2025 suppository trial is not that replication either, because it tested a topical product by a different route. The dosage page shows the studied amounts across all trials, and 3 grams daily is the only dose with vaginal data behind it. Promising is the accurate grade. If a second trial appears, this page will say so.

The practical version

1. Dose: 3 grams of oil daily, the studied amount, with food. Liquid or softgels both deliver it, and the oils that name the plant part on the label are the ones worth starting from, because a bottle that will not say berry or seed cannot tell you what you are actually dosing.
2. Timeline: the trial measured at three months. Judging at three weeks judges nothing.
3. Check interactions first: one study at 5 grams daily saw reduced platelet aggregation, so blood thinner users and pre-surgery patients need the safety hub before the bottle.

The menopause page places this trial in the wider life-stage picture. Persistent pain, bleeding, or symptoms that ignore both oil and moisturizer belong in front of a doctor.

Frequently asked questions

Does sea buckthorn oil help vaginal dryness?

One randomized, placebo-controlled trial says yes, modestly. 116 postmenopausal women took 3 grams of oil daily for three months, and the oil group had about three times the odds of improved vaginal epithelial integrity versus placebo. It is a non-hormonal support option, not a replacement for topical estrogen.

Does sea buckthorn work like estrogen?

No, and the trial proved that specifically. Vaginal pH and the maturation index did not change, which means the oil was not acting like estrogen. That non-hormonal profile is exactly why it interests women who cannot or do not want to use estrogen therapy.

How long does sea buckthorn take to work for vaginal dryness?

The trial measured results at three months of 3 grams daily, and that is the only honest timeline the data offers. Judging at three weeks judges nothing. If three months of the studied dose changes nothing for you, the next step is a doctor conversation about stronger options, not a higher dose.

Is the sea buckthorn vaginal suppository the same as taking capsules?

No, and the difference matters. A 2025 trial in 368 postmenopausal women compared a vaginal sea buckthorn suppository against an estrogen ointment before a cervical exam and found no significant difference between them, with fewer whole-body side effects on the sea buckthorn side. That was a licensed pharmacy product placed in the vagina, a compound formula rather than pure sea buckthorn, and the trial set no non-inferiority margin, so the accurate reading is no difference detected rather than proof of a match. The capsules this page covers are swallowed, and that oral route has never been tested head to head against estrogen. Do not read the suppository result as proof that swallowing oil matches estrogen, and do not put a capsule meant for swallowing anywhere else.